Evaluating the diagnostic efficacy of 12-point lung ultrasound in detecting COVID-19 lung lesions: a comparative study with low-dose chest CT scan

Objective: Chest computed tomography (CT) scans are the gold standard for identifying pulmonary involvement in pneumonia-like COVID-19 cases, albeit with certain drawbacks such as radiation exposure and high costs. This research aims to evaluate the diagnostic precision of a 12-point lung ultrasound (LUS) against a low-dose chest CT scan in identifying lung lesions associated with COVID-19. Methods: The study incorporated 100 consecutive patients, aged over 18 years, exhibiting suspected clinical symptoms of COVID-19 or inpatients requiring a low-dose chest CT scan for diagnosing asymptomatic COVID-19 lung lesions. All participants underwent a 12-point LUS, followed by a low-dose chest CT scan. Data analysis was conducted using STATA-16, with descriptive results presented as mean and standard deviation. Results: The study comprised 60 males and 40 females, with an average age of 43.0±16.9 years. The mean distribution of the patients’ clinical features was calculated. The LUS demonstrated a sensitivity, specificity, and positive and negative predictive values of 97.5%, 86.4%, 83.3%, and 98%, respectively. Conclusion: The 12-point LUS exhibited high sensitivity and specificity in assessing pulmonary involvement in COVID-19 patients. Therefore, lung ultrasound results, combined with medical history and clinical examination, can serve as an effective triage tool for COVID-19 patients. The LUS, a swift, safe, and effective ionization tool, can potentially replace chest CT scans in scenarios such as CT scan unavailability, intensive care management, and patient follow-up.